✦ LIBER ✦

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

✍ Scribed by J. Tabernero; E. Van Cutsem; R. Lakomy; J. Prausova; P. Ruff; G. Van Hazel; V Moiseyenko; D. Ferry; J. McKendrick; K. Soussan-Lazard; E. Boelle; C. Allegra

Book ID: 117660604
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 50 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70105-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

✍ Tabernero, Josep; Van Cutsem, Eric; Lakomý, Radek; Prausová, Jana; Ruff, Paul; v 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 706 KB

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

✍ Tannock, Ian F; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fl 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 310 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

6077 A meta-analysis of the CRYSTAL and

6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status

✍ Van Cutsem, E.; Rougier, P.; Köhne, C.; Stroh, C.; Schlichting, M.; Bokemeyer, C 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Quality of life in patients with advance

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

✍ Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Maciej Krzakowski; Sung Hy 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 230 KB